Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12409197-B2

Patent

Publication Date

2025-09-09

Expiration Date


Abstract

Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.

Core Innovation

The claimed invention is a method of functionally populating the gastrointestinal tract of a human subject in need thereof. The method comprises administering a capsule encapsulating three nonidentical isolated bacterial species capable of forming a spore: Clostridium orbiscindens, Clostridium bolteae, and Lachnospiraceae bacterium 5_1_57FAA. The claim specifies a sequence identity requirement [procedural detail omitted for safety] for Clostridium orbiscindens, and the combination decreases or inhibits pathogenic bacterial growth or colonization.

The disclosure reports screening results, bacterial-community engraftment, pathogen-inhibition assays, and animal and clinical outcomes for bacterial ecologies. Documented contexts include functional restoration of the gastrointestinal microbiome and therapeutic applications for dysbiosis and infections, including Clostridium difficile. Because background details are omitted in the provided text, the specific problem addressed is not explicitly described in patent. Furthermore, the provided description does not establish efficacy specifically for the recited three-species combination.

Claims Coverage

The claim set identifies one independent claim comprising four inventive features.

Method of functionally populating the gastrointestinal tract

The claim provides a method of functionally populating the gastrointestinal tract of a human subject in need thereof by administering a composition.

Capsule encapsulating three nonidentical bacterial species

The composition comprises a capsule encapsulating a first, second, and third nonidentical isolated bacterial species capable of forming a spore, comprising Clostridium orbiscindens, Clostridium bolteae, and Lachnospiraceae bacterium 5_1_57FAA.

Sequence identity requirement for Clostridium orbiscindens

Clostridium orbiscindens comprises a 16S rDNA sequence identity requirement relative to a reference sequence [procedural detail omitted for safety].

Inhibition of pathogenic bacteria

The combination of the three bacterial species is capable of decreasing or inhibiting the growth or colonization of at least one type of pathogenic bacteria.

The independent claim covers administering an oral capsule containing the three specified, nonidentical spore-forming bacterial species to functionally populate the gastrointestinal tract and decrease or inhibit pathogenic bacterial growth or colonization.

Stated Advantages

The combination of the three bacterial species is capable of decreasing or inhibiting the growth or colonization of at least one type of pathogenic bacteria.

Tested bacterial combinations exhibit inhibition and synergy against Clostridium difficile and vancomycin-resistant enterococci.

Documented Applications

Functionally populating or restoring the gastrointestinal microbiome of a human subject in need thereof using the claimed capsule composition.

Therapeutic use for dysbiosis and clinical treatment of Clostridium difficile-associated disease to resolve disease and increase gut microbiome diversity.

Inhibition of pathogenic bacteria, including vancomycin-resistant enterococci, Klebsiella pneumoniae, and Morganella morganii, alongside bacterial-community engraftment.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.